About CMRI

Children's Medical Research Institute (CMRI) has around one hundred and fifty scientists and research students, working in teams that operates thirteen research units and world-leading expertise in four main areas of research: Cancer, Neurobiology, Embryology and Gene Therapy.

Our aim is to accelerate research into children’s genetic diseases, birth defects and childhood cancer to find better treatments and cures, so Australian kids can live normal, happy lives.

How we're fighting kids' cancer

One of the most important differences between cancer cells and normal cells is that cancer cells can keep on multiplying an unlimited number of times, but normal cells eventually stop dividing. This difference is where we have chosen to focus our attention, as it has the potential to provide an answer to one of the most problematic issues in cancer treatment – how to kill cancer cells without harming healthy cells.

It is the progressive shortening of telomeres (the DNA at the ends of chromosomes) which sets a limit on the number of times normal cells can divide. This does contribute to aging, but also acts as a powerful protection against normal cells becoming cancerous.

Cancers evade this limitation, and effectively become ‘immortal’, by switching on one of two telomere lengthening mechanisms: an enzyme called telomerase or the Alternative Lengthening of Telomeres (ALT) mechanism. If blocking telomere lengthening mechanisms is to become a viable option for cancer treatment, we need a thorough understanding of both mechanisms.

Partnering to find cures

The ACRF International Centre for the Proteome of Human Cancer (ProCan®) is a facility and international research project located at Children's Medical Research Institute (CMRI) in Sydney Australia. It was established with a $10 million grant from the Australian Cancer Research Foundation (ACRF) and has received subsequent funding from government, charitable organisations and members of the community. This world-first initiative was developed by Professors Phil Robinson and Roger Reddel at CMRI.

ProCan is developing a database of information to advance scientific discovery and enhance clinical treatment worldwide. This database will mean doctors can more precisely diagnose cancer and effectively narrow down the best type of currently available treatment to target a patient's individual cancer diagnosis. This is personalised, precision medicine.

ProCan will provide a major step forward for cancer diagnosis and treatment.

Over the next 5-7 years, Children’s Medical Research Institute will work with leading cancer researchers, hospitals, universities and other institutes throughout Australia and around the world to analyse over 70,000 samples of all types of cancer from all over the world.

These cancer biopsies also come with the patient’s full history and the treatment plan they received. Advanced data science and software engineering will be used to compare the protein data with the de-identified information that is already available for each cancer, including clinical records such as pathology test results, genetic analyses, genome sequencing, and any previous responses to cancer treatment. This proteogenomic approach to understanding cancer is crucial to speeding up the search for cures.

The data gathered will help develop a library of information to advance scientific discovery and improve cancer treatments by helping doctors rapidly choose the best type of currently available treatment for their patients’ individual diagnosis. All this without having to waste weeks and months trialling medication that may prove to be ineffective for treating that type of cancer.

The information generated by ProCan will be free for anyone to access. This will help scientists all over the world studying cancer. What’s more, the library of information created will be a point of reference that can be used now and, in the future, to aid rapid diagnosis and treatment planning.

ProCan was invited to join the ‘Cancer Moonshot’ initiative led by the United States’ Government and is also part of the EU Horizons 2020 project involving 20 countries called Individualised Paediatric Cure (iPC).

CMRI cancer unit's major achievements:

2019 ProCan was the first program in the world to analyse the proteomes of 10,000 human cancers.

2018 CMRI’s Dr Tony Cesare makes a ground-breaking discovery around regulation of telomere loop structure, which has major implications for conditions ranging from cancer to aging and heart disease.

2016 ProCan was established with a $10 million grant from the Australian Cancer Research Foundation (ACRF). ProCan is a world-first initiative developed by Professors Phil Robinson and Roger Reddel which launched in September 2016.

2015 We discovered that cancer cells which switch on Alternative Lengthening of Telomeres (ALT) by losing ATRX gene function are much more fragile than normal cells when exposed to various forms of stress. We are using this knowledge to design treatments that will kill ALT-positive cancers with minimal side effects on normal cells.

2014 CMRI identified a gene that causes inherited bone marrow failure and uncovered a key anti-cancer target for ALT cancers - some of the most aggressive types.

2013 CMRI demonstrated that ALT has a normal counterpart in cells and developed a new model system for studying the ALT mechanism.

2012 Our scientists were involved in an international study identifying key genetic change (loss of ATP-dependent helicase) in ALT .

2011 We licensed C-circle assay for research use as a test for ALT cancers, helping identify the disease in kids easier and earlier.

2009 Our scientists developed C-circle assay for measuring ALT activity in cancer and discovered a telomere trimming mechanism that could one day be exploited to target and kill cancer cells.

2007 We were the first in the world to identify composition of active telomerase enzyme complex in human cells.

2000 CMRI demonstrated that ALT involves DNA recombination, becoming the first in the world to show this underlying mechanism.

1999 Our scientists found a diagnostic marker for ALT, called APBs, and also showed that unknown factors in normal cells can repress ALT cancers.

1995 We discovered ALT mechanism of telomere maintenance in cancer, which created an entirely new field of research .

For more information on CMRI, visit www.cmri.org.au.